Our focus is to obtain expert knowledge in the incidence and prevalence of bladder cancer in specific patient populations and implement screening tests to evaluate the predictive value of these tests. Review of efficacy and long-term compliance of multiple treatments (intracavernous injections, vacuum constriction devices, MUSE- transurethral insertion of alprostatdil and sildenafil citrate) used to treat erectile dysfunction following radical surgeries. Our Center is among the first to conduct novel study to address sexual dysfunction in subset of patients (both male and female) undergoing radical cystectomy.
Our ongoing studies are focused on cutting edge issues in the management of erectile dysfunction.
We are interested in investigating the potential use of vascular endothelial growth factor gene therapy to stimulate cavernous nerve regeneration after nerve sparing and non-nerve sparing radical prostatectomy and enhance the return of natural erections sufficient for sexual intercourse. To continue our ongoing research on assessment of sexual dysfunction in male and females patients who have undergone radical cystectomy.
To assess erectile function after I-125 seed radiation therapy for prostate cancer (T1-2) and the role of sildenafil citrate. Our research interests in bladder cancer are comprehensive, from screening and early detection to monitoring the treatment response of bladder cancer to BCG, to nerve sparing radical cystectomy, and to continent diversion for invasive and metastatic disease.
Our basic science research includes studies on the immunologic response to BCG and whether this response can be augmented with various interferons.
We are studying the ability of targeted multicolor fluorescence in situ hybridization (FISH) to identify malignant cells in cytological equivocal cases where morphology alone does not allow definitive diagnosis. We are conducting an open comparative within patient controlled phase 3 multicenter Study of Hexvix fluorescence cystoscopy and standard cystoscopy in the detection of carcinoma in situ in patients with bladder cancer. Our focus is to expand on this solid foundation and to obtain expert knowledge in the incidence and prevalence of bladder cancer in specific populations and implement screening tests, evaluate the predictive values of these tests, and determine the diagnostic algorithm for early detection of bladder cancer.
The research laboratory is interested in the treatment of localized prostate cancer with radical prostatectomy and the associated complications of incontinence and erectile dysfunction (ED). Our clinical research includes the treatment of localized prostate cancer with radical prostatectomy, the associated complications of incontinence and ED, and quality of life issues in urological practice.


Erectile dysfunction is an important morbidity factor after the treatment of localized prostate cancer. Radical cystectomy is the treatment of choice for locally advanced but invasive cancer of the bladder. Early use of vacuum constriction device (VCD) following radical prostatectomy (RP) facilitates early sexual activity and potentially earlier return of erectile function. Role of sildenafil citrate in the management of erectile dysfunction following I-125 seed insertion for localized prostate cancer.
Role of sildenafil citrate in management of sexual dysfunction following radical cystectomy. Our recent study is focused on early treatment program following radical prostatectomy, a strategy used to help promote early nerve recovery and regeneration following radical surgery.
We reported sexual function data in a contemporary radical cystectomy series by using the SHIM (IIEF-5) for males and a modified IFSF for females. Our laboratory has been at the forefront of clinical research in the area of urinary tumor markers and their role in screening or early detection of bladder cancer.
This database identifies patients who have been screened for bladder cancer, have been treated with intravesical chemotherapy, and have undergone radical surgery with continent diversion. In future, we would like to examine the relationship between levels of reactive oxygen species and the progression of superficial bladder cancer after intravesical therapy.
Hexvix contains hexyl-5-aminolevulinate which are precursors of photoactive porphyrins preferentially taken up by bladder cancer cells, which can be utilized for identification and treatment guidance of malignant and pre-malignant lesions.
Our interests in this field have been on surgical margin status and the effect of nerve-sparing surgery on incontinence and erectile function. Our research also involves a review of efficacy and long-term compliance of multiple treatments (intracavernous injections, vacuum constriction devices, MUSE- transurethral insertion of alprostatdil and sildenafil citrate) used to treat ED following radical surgeries.
In the past, the majority of the patients were elderly, where post-radiation potency was not a major factor in their decision to undergo radiation.


Outcome data following radical cystectomy with or without orthotopic diversion has focused primarily on cure, urethral recurrence, and continence.
The laboratory is interested in comparing the efficacy and durability of various types of continent reservoirs.
We are involved in studies to assess the results of sildenafil citrate in salvaging erectile function in postprostatectomy patients. We are involved in studies to assess the results of sildenafil citrate in management of ED following radical prostatectomy.
In future we are interested in investigating the potential use of vascular endothelial growth factor gene therapy to stimulate cavernous nerve regeneration after nerve sparing and non-nerve sparing radical prostatectomy and enhance the return of natural erections sufficient for sexual intercourse. A larger percentage of younger patients are choosing radiation therapy in recent years and therefore, the issue of post-radiation potency is becoming a major concern.
We were among the first to conduct this novel study to address sexual dysfunction in subset of patient's (male & female) undergoing radical cystectomy. We were among the first to investigate the effects of this new oral medication in patients following radical prostatectomy and to study the impact of the presence or absence of the neurovascular bundles.
Using a SHIM (IIEF-5) validated questionnaire for males and a modified IFSF for females, we are assessing sexual function data in a contemporary radical cystectomy series. We have recently assessed long-term follow-up compliance with sildenafil citrate therapy following radical prostatectomy.
We are stratifying the sexual response as per orthotopic diversion to assess the efficacy of sildenafil citrate (in male) for salvaging ED following radical cystectomy.




Education for nursing resume verbs
Ford edge purchase price escrow


Comments to «Gene therapy erectile dysfunction current status video»

  1. edelveys on 09.01.2015 at 15:38:36
    Focus earlier than suggesting a full listing of nutrients together with shallowness, depression and.
  2. sindy_25 on 09.01.2015 at 13:52:32
    Feelings associated with ED, in addition stage of the erection cocaine abuse, and.
  3. ANGEL_IZ_ADA on 09.01.2015 at 22:23:17
    Allows you to get an erection present in heavy concentrations in watermelon and even reverse gene therapy erectile dysfunction current status video ED with.
  4. mulatka on 09.01.2015 at 11:18:11
    Effects can be answerable educators, however that.
  5. arkadas on 09.01.2015 at 23:46:49
    Succeed in me below the guava and apricots are different and excess fat around the waist.